|
|
The Pipeline Project Needs Your Help

Contact Us
What's New...
Repairing the Parkinson's
Pipeline, by Robin Elliott,
Executive Director of the Parkinson’s Disease
Foundation
Response to Robin Elliott, by
Peggy Cohen, Ph.D., Project Director
Terminated
Experimental Treatments
Opinion:
Is there an important pattern in
the seemingly uninterrupted failure of drugs and biologics?
Read this Op/Ed
On the Toxicity of GDNF:
A challenge to Amgen's monkey GDNF toxicity study
Book:
"Monkeys in the
Middle: How One Drug Company Kept a Parkinson's Disease Breakthrough Out of
Reach" by investigative journalist Nick Nelson, has just been
published and is available on
Amazon.
The "Access, Compassion,
Care, and Ethics for Seriously Ill Patients Act" or the Access
Act (S3046 ) was introduced in the Senate in May. It is a bill to amend the
Federal Food, Drug, and Cosmetic Act to create a new conditional approval system
for drugs, biological products, and devices that is responsive to the needs of
seriously ill patients, and for other purposes. For Details see
Library of Congress, Thomas
Past What's
New items have been archived on this page. |
The Parkinson Pipeline
Project is supported by
the Parkinson's Disease Foundation (PDF),
a 501(c)3 Corporation
headquartered in New York City.
Tax deductible donations to the Parkinson
Pipeline Project, made through this website to
Donate.net, go
to the PDF designated for use by the Parkinson Pipeline Project.


Contact Us
|
|
|
| |
|
What is the Pipeline Project?
The Parkinson Pipeline Project
is a grassroots group of advocates whose goal is to provide
the patient perspective in the treatment development
process. Through education, consultation, and participation
with all stakeholders - including industry and the FDA - the
Parkinson Pipeline Project hopes to increase clinical trial
participation and accelerate approved treatment options.
New PD treatments are followed from pre-clinical development
to approval in the Pd Pipeline Database found on our
website.
More info...
"The missing ingredient in the development of new therapies is the voice of the patient."
Perry Cohen, Ph.D., Project Director
|
|
 |
"Ethical Issues in Clinical Neuroscience Research: A Patient's Perspective"
W ritten
by Parkinson Pipeline Project members Published in
Neurotherapeutic, Vol. 4, No. 3, 2007.
Read the article
|
 |
 |
|
|

To
access PD Pipeline database records related to
these news items - please click on
-
-
Neurologix Initiates Recruitment
for Phase 2 Parkinson's Disease Trial (8/19/08)
Read press release

-
Orally Disintegrating Selegiline (Zelapar)
Allows Parkinson's
Disease Patients to Lower Dopamine Agonist
Dose (6/27/08)
Read press release

-
Spheramine -
Titan's potential cell-based
treatment for Parkinson's Disease "failed in a Phase IIb study, and likely won't be continued by partner
Bayer Schering Pharma. "
Read article. (7/2/08)

-
"Understanding the Recent
Announcement about Azilect®
and its Potential to
Slow the Progression of Parkinson’s Disease"
Statement from the Parkinson's Disease Foundation
(PDF)
Read statement.
-
Teva Pharmaceutical
Industries Ltd. announced the
successful completion of ADAGIO, the
phase III study designed to demonstrate
that AZILECT 1 mg tablets can slow down
the progression of Parkinson's disease."
(6/15/08) Read
full press release

- FDA approval
received for
Requip XL 24-Hour - once- a-day
dopamine agonist (6/1/3/08)
Read press release

-
Kyowa Pharmaceutical Suspends
Development of Istradefylline (KW-6002) in
North America. Read sponsor's letter to the PD
community (6/3/08)
Read press release
Genetic mechanisms linked to Parkinson's
disease uncovered. Researchers show direct
pathway that could be targeted for drug therapy
(7/24/08)
Read the full article
Metabolomic Profiling to Develop Blood
Biomarkers for Parkinson's Disease
(06/08)
Can We Prevent Parkinson's Disease With N-3
Polyunsaturated Fatty Acids?
Read the full article - In four parts
FDA Scraps Helsinki Declaration
on Protecting Human Subjects"
Read full opinion
FDA
Signals High Bar for Stem Cell Treatments.
Read full article and comments in Wall
Street Journal Health Blog.

For archived op/eds see
Op Eds / Perspectives
|
|
 |
|
|
|
Your access to
and use of the information contained in this web site is subject to this Terms
and Conditions of Use Agreement. By accessing and using this web site, you
accept this Terms and Conditions of Use Agreement.
The contents of this website and
all communications with Parkinson Pipeline Project (PPP) are solely for
information purposes and are not intended as medical advice. While we make
every effort to assure that the information is accurate and up to date, an error
may >occasionally occur. All information and materials are provided AS IS
without any warranty of any kind. In no event will the PPP be held liable
for any damages arising out of information contained in our website.
If any
provision of this Terms and Conditions of Use Agreement is held to be unlawful,
void, or unenforceable, then such provision shall be deemed severed without
affecting the enforceability of all remaining provisions.
|
|
|
Copyright © 2004-2007 Parkinson Pipeline
Project.
All rights reserved. Revised:
08/31/08
|
|